The health sector represents a large and growing global market. Portugal has developed strengths in research, education, and industry in areas like pharmaceuticals, medical devices, and services. It produces thousands of life sciences graduates each year and has growing R&D investment and scientific publications. Several Portuguese companies are competitive global players in their niches. However, to fully capitalize on opportunities, Portugal aims to strengthen commercialization, international promotion, and cooperation across its health value chain through groups like Health Portugal Cluster. Their goals are to establish Portugal as a leader in select market and technological areas through large collaborative projects in areas such as aging technologies and translational research.

1. HEALTH SECTOR
overview, trends and opportunities
BETA-TRENDS SEA & LIFE SCIENCES CLUSTERS
 05 September 2012 
11

2. The global Health market(s)
Total expenditure on health as % of GDP (2010)
Source: WHO
:: Total health expenditure: US$ 6.5 x1012
:: Pharmaceutical market: US$ 850 x109
:: Medical device market: US$ 300 x109

3. Creating value: the Health industries
:: The Health value chain
Indústria
Química I&D, TIC
Elementos auxiliares de
Serviços às diagnóstico
empresas
(consultoria)
Prestação de cuidados
I&D, TIC
Cuidados de
saúde
Produtos
Farmacêuticos
Indústria UTENTE
Dispositivos médicos Comércio por
e consumíveis grosso
Papel, Edição,
Impressão
Farmácias
Plástico
Vidro
Metalúrgia Indústria Distribuição/Comércio
Electrónica
Source: ISEG

4. Is Portugal a competitive player?

5. Is Portugal a competitive player?
:: The R&D investment has been growing consistently
# Company / Group R&D Expenditure (€)
6 Bial – Portela & Cia, SA 43,013,339
16 Alert – Life Sciences Computing, SA 12,041,623
30 Hovione FarmaCiencia, SA 6,167,050
33 Tecnimede – Sociedade Técnico-Medicinal, SA 5,754,878
52 Biocant – Associação de Transferência de Tecnologia 3,133,354
55 Eurotrials – Consultores Científicos, SA 2,927,239
61 Ablynx, SA 2,610,585
Number of researchers and SA
62 Bluepharma – Indústria Farmacêutica, PhDs in selected
2,544,467
Health Grupo Azevedos
94 sector companies (2009) 1,713,365
98 Grupo AtralCipan Researchers 1,663,999
PhDs
Company / Group
100 Lilly Portugal – Produtos Farmacêuticos, Lda (FTE) (FTE)
1,646,827 ~83 M€
Ablynx, SA 22.8 9.8 (#5)
R&D Expenditure
# Hospital / Group of Hospitals
Alert – Life Sciences Computing, SA 210.4 (€)
10.2 (#4)
Bial – Portela & Hospitalar do Porto, EPE
1 Centro Cia, SA 53.5 5,449,273
14.1 (#2)
2 Centro Hospitalar de Lisboa Central, EPE 4,036,972
Biocant – Associação de Transferência de Tecnologia 31.2 10.8 (#3)
3 Centro Hospitalar de Lisboa Norte, EPE 3,385,751
Bluepharma – Indústria Farmacêutica, SA 34.1 1.0
4 Hospital de São João, EPE 2,761,268
Critical Health, SA 14.8 1.0
5 Hospitais da Universidade de Coimbra, EPE 2,635,503
Eurotrials – Consultores Científicos, SA 68.0 2.0
6 Centro Hospitalar de Lisboa Ocidental, EPE 2,300,726
Grupo AtralCipan 14.3 1.4
7 Grupo José de Mello Saúde, SGPS, SA 1,219,110
Grupo Azevedos 10.2 n.a.
8 Instituto Português de Oncologia do Lisboa Francisco Gentil, EPE 1,068,554
Hovione FarmaCiencia, SAde Oncologia do Coimbra Francisco Gentil,83.0
9 Instituto Português EPE 22.0 (#1)
1,036,725
Tecnimede – Sociedade Técnico-Medicinal, SA Francisco Gentil, EPE
10 Instituto Português de Oncologia do Porto 49.5 1.0
954,018 ~25 M€
Source: GPEARI/MCTES

6. Is Portugal a competitive player?
:: Portugal has a growing number of highly-qualified people ...
Higher education: Students enrolled and graduates
Graduates Enrolled
Education area
(2006-2007) (2007-2008)
Biology and Biochemistry 1,819 9,696
Dental sciences 637 3,522
Pharmaceutical sciences 893 6,896
Nursing 5,912 19,774
Medicine 1,434 9,053
Public health services 253 603
Diagnostic and therapeutic
3,001 7,468
technologies
Therapy and rehabilitation 2,132 6,976
Engineering: biomedical, clinical,
304 1,525
pharmaceutical, health
Health (not included in other areas) 8 169
Total 16,393 65,682
Source: GPEARI / MCTES

7. Is Portugal a competitive player?
:: ... including PhDs ...
PhDs in Life, Medical and Health Sciences
200
180
160
140
No. of PhDs
120
100
80
60
40
20
0
Years
Life Sciences Medical and Health Sciences
Source: GPEARI / MCTES

8. Is Portugal a competitive player?
:: ... and the value chain now employs more researchers and PhDs.
Number of researchers and PhDs in selected
Health sector companies (2009)
Researchers PhDs
Company / Group
(FTE) (FTE)
Ablynx, SA 22.8 9.8 (#5)
Alert – Life Sciences Computing, SA 210.4 10.2 (#4)
Bial – Portela & Cia, SA 53.5 14.1 (#2)
Biocant – Associação de Transferência de Tecnologia 31.2 10.8 (#3)
Bluepharma – Indústria Farmacêutica, SA 34.1 1.0
Critical Health, SA 14.8 1.0
Eurotrials – Consultores Científicos, SA 68.0 2.0
Grupo AtralCipan 14.3 1.4
Grupo Azevedos 10.2 n.a.
Hovione FarmaCiencia, SA 83.0 22.0 (#1)
Tecnimede – Sociedade Técnico-Medicinal, SA 49.5 1.0
Source: GPEARI/MCTES

9. Is Portugal a competitive player?
:: The scientific production has been increasing sharply ...
Scientific production: Life, Medical and Health Sciences
3500
3000
2500
No. of publications
2000
1500
1000
500
0
Years
Life Sciences Medical and Health Sciences
Source: GPEARI / MCTES

10. Is Portugal a competitive player?

11. From knowledge
to market
1111

12. Key figures
129 Members
R&D Institutions + Universities
3100 researchers in Health
2000 PhDs
Hospitals
8500 physicians
8000 beds
17 M€ in R&D
Pharma & Biotech
1250 M€ turnover
80 M€ in R&D
4000 employees
130 PhDs
Medical Devices & Services
570 M€ turnover
30 M€ in R&D
6000 employee
30 PhDs
To become a Member, please visit www.healthportugal.com

13. Mission
To turn Portugal into a competitive player in the
research, design, development, manufacturing
and commercialization of health-related products
and services,
in selected market and technological niches, targeting
the most demanding and relevant international markets,
based on the recognition of its excellence,
technological level and competences in the field of
innovation.

14. Strategic vision
+ social and economical development
+ business
+ exports
+ employment (qualified)
+ health
STRATEGIC OPTIONS
 well-being / ageing
 diseases (neurodegenerative, cancer,
Knowledge / R&D + I cardiovascular, osteoarticular degenerative,
. diseases inflammatory, infectious and metabolic)
. pharmaceutical  e-health (AAL-Ambient Assisted Living,
. medical devices
. biotechnology process integration and automation)
. nanotechnology
Enterprise dynamics Public support / Demonstration actions
. healthcare . support to investment and innovation
. pharmaceutical . public procurement
. biotechnology . FDI attraction
. auxiliary diagnostic means . training
. medical devices Management . idea contests
. ICTs . pilot projects
. process automation
. productivity

15. Objectives
in 3-5 years in 10 years
> to change the current
knowledge-exploitation
paradigms  5 new drugs
> generalization of translational
research and clinical research  50 new diagnostic
> bioengineering ecosystems methods/ devices/
> to improve the cooperation/ services
coopetition environment
> international recognition  4 000 million € turnover
> strengthen the company (>70% exports)
base and the R&D system

16. Horizontal Anchor Projects (promoted by HCP)
:: Translational Research
Research “from bench to bedside and back again”...
:: Intellectual Property and Technology Transfer
Protection and exploitation of new knowledge and technologies...
:: International Promotion & Networking
Promoting Portugal globally as a competitive player in Health...
Promoting and fostering cooperation amongst players...
... to turn knowledge into health and wealth

17. Flagship Projects (co-promoted by HCP members)
:: AAL4ALL – Ambient Assisted Living for All
Mobilization of an industrial ecosystem for the massification of products
and services in the area of Ambient Assisted Living (AAL), focused on
the definition of specifics standards (for products and services).
Investment: 8.2 M€ (QREN 5.0 M€)

18. Flagship Projects (co-promoted by HCP members)
:: Do IT – Development and Operation of Translational Research
Development of translational research strategies and organizational
models applicable to the entities of the Portuguese health value chain
(companies, R&D institutions and hospitals).
Development of innovative and competitive products and services for
the global Health market.
Investment: 8.6 M€ (QREN 5.0 M€)

20. Some trends and opportunities ahead
in the Health sector

21. Some trends and opportunities ahead
:: A changing landscape: different needs, different demands...
▪ Increased longevity and ageing
populations.
▪ New epidemiologic patterns:
. Changes in the main causes of death.
. Chronic diseases.
. Emerging/re-emerging infectious diseases.
. Pandemics.
▪ Increased purchasing power (namely in
highly-populated countries with emerging
economies).
▪ Citizens/users more informed, more
demanding and with higher (geographic)
mobility.
▪ Cost containment.
▪… Source: WHO

22. Some trends and opportunities ahead
:: ... new opportunities!
[image]
[image]
[image]

23. Some trends and opportunities ahead
:: ... new opportunities!
[image]

24. Some trends and opportunities ahead
:: Changing paradigms in healthcare delivery: P4 Medicine
▪ Predictive
▪ Preventive
[image]
▪ Personalized
▪ Participatory

25. Some trends and opportunities ahead
:: Typologies of products, processes and services: a few examples.
Sectors / Resources / Technology Platforms | Typologies of products, processes and services
Market Biotechnology Endogenous / Organization /
areas ICT & Electronics Nanotechnology
& Omics Natural resources Management
▪ Targeted therapies
▪ Biopharmaceuticals
▪ New antibiotics
▪ In-situ drug delivery ▪ Natural compounds
Pharma ▪ Drugs for neglected ▪ Bioinformatics tools
systems (sea, plants, ...)
diseases
▪ Biomarkers
▪ Vaccines ▪ Citizen
empowerment
▪ Ambient Assisted ▪ Nanobots ▪ P4 medicine
▪ Regenerative Living products ▪ Biomedical and ▪ New business
Medtech & medicine ▪ Point-of-care molecular imaging models
Diagnostics ▪ Companion products ▪ Minimally invasive ▪ New financing
diagnostics ▪ Biomedical and surgery models
biological imaging ▪ Nanoimplants ▪ Open innovation
▪ AAL services
Healthcare & ▪ e-Health /
▪ Health/medical
Wellbeing telemedicine
tourism
delivery ▪ Computer aided
diagnostics

26. www.healthportugal.com
www.scienceportugal.com
Luís Soares
lsoares@healthportugal.com
Rua Eng.º Frederico Ulrich, 2650
Moreira da Maia
4470-605 Maia
PORTUGAL
Tel: (+351) 220 968 183
info@healthportugal.com 26
26
www.healthportugal.com